A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Lumendi Files for 510(k) Clearance for 2 New Products

Company Achieves New Milestone with 3000 Therapeutic Procedures Completed Across U.S., Europe, and Asia Using DiLumen™ EIP

Lumendi, LLC announced it has filed for U.S. Food and Drug Administration (FDA) 510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device intended for endoscopic mucosal resections (EMR) and difficult colonoscopies.

The new design, based on the long-standing success of the DiLumen EZ-Glide platform, has been modified and streamlined. “This new device will serve to enhance our product portfolio and bring further improvements to complex polyp resections through the procedure known as Endoscopic Mucosal Resections (EMR). EMR represents the majority share of polyp resection procedures worldwide, with over 1 million cases annually,” said Dr. Peter Johann, CEO, Lumendi, Ltd.

Simultaneously, Lumendi has filed for U.S. Food and Drug Administration 510(k) clearance of a second device, named DiLumen C¹, which is designed to facilitate complex polyp resection in the colon. C¹’s design offers a single working channel that accommodates an atraumatic grasper, which provides more direct tissue manipulation and traction. The C¹ and Grasper will improve enbloc dissection of precancerous and non-invasive cancerous polyps, a procedure known as Endoscopic Submucosal Dissection (ESD).

Following several years of feedback from leading clinicians, Lumendi believes that inadequate tissue manipulation and traction, combined with ineffective cutting, dissecting, and cauterizing, continues to be a major challenge for many therapeutic procedures in the digestive tract. These are the ninth and tenth devices Lumendi has developed, as the company continues to advance minimally invasive endolumenal therapies.

Lumendi is pleased to also report that, to date, clinicians in the U.S., several EU countries including Germany, France, Italy, Spain, and the U.K., as well as at the Chinese University of Hong Kong, have completed over 3,000 procedures with the commercially available DiLumen EZ Glide.

“These new products along with the strong market adoption of DiLumen EZ Glide will help accelerate Lumendi’s continued vision to migrate many invasive gastrointestinal surgeries that require hospital stays, higher risks of infection and longer recoveries to much less invasive endoluminal procedures with low complication rates, no hospital stays and very minimal recovery times.” said Dr. Johann. “In addition, based on our success impacting therapeutic procedures in the colon and using our current technology, we have recently started a development program in upper GI interventions that we expect will lead to less invasive and less costly procedures with equal or better outcomes.”

The DiLumen EZ¹ and C¹ are part of a growing platform of accessories that work in conjunction with endoscopes and gastroscopes used in the large intestine that assist with navigational access, optical visualization, diagnosis and endotherapeutic treatment.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy